Corindus Vascular Robotics, Inc.
If you purchased Corindus Vascular Robotics, Inc. securities and would like to join the action, please click "Join This Action" below.
CORINDUS MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE SALE OF CORINDUS VASCULAR ROBOTICS, INC. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – CVRS
August 8, 2019.
New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Corindus Vascular Robotics, Inc. (NYSEAMERICAN: CVRS) to Siemens Healthineers AG for $4.28 per share is fair to Corindus shareholders. On behalf of Corindus shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
The Corindus merger investigation concerns whether Corindus and its Board of Directors violated the federal securities laws and/or their fiduciary duties to shareholders by failing to: (1) obtain the best possible price for Corindus shareholders; (2) determine whether Siemens is underpaying for Corindus; and (3) disclose all material information necessary for Corindus shareholders to adequately assess and value the merger consideration.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.